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The cutting balloon (CB) is a specialized device designed
to create discrete longitudinal incisions in the atheroscle-
rotic target coronary segment during balloon inflation.
Such controlled dilatation theoretically reduces the force
needed to dilate an obstructive lesion compared with
standard percutaneous transluminal coronary angio-
plasty (PTCA). We report a multicenter, randomized trial
comparing the incidence of restenosis after CB angio-
plasty versus conventional balloon angioplasty in 1,238
patients. Six hundred seventeen patients were random-
ized to CB treatment, and 621 to PTCA. The mean ref-
erence vessel diameter was 2.86  0.49 mm, mean
lesion length 8.9  4.3 mm, and prevalence of diabetes
mellitus in patients was 13%. The primary end point, the
6-month binary angiographic restenosis rate, was
31.4% for CB and 30.4% for PTCA (p  0.75). Acute
procedural success, defined as the attainment of <50%
diameter stenosis without in-hospital major adverse car-
diac events, was 92.9% for CB and 94.7% for PTCA (p
0.24). Freedom from target vessel revascularization was
slightly higher in the CB arm (88.5% vs 84.6%, log-rank
p 0.04). Five coronary perforations occurred in the CB
arm only (0.8% vs 0%, p  0.03). At 270 days, rates of
myocardial infarction, death, and total major adverse
cardiac events for CB and PTCA were 4.7% versus 2.4%
(p  0.03), 1.3% versus 0.3% (p  0.06), and 13.6%
versus 15.1% (p  0.34), respectively. In summary, the
proposed mechanism of controlled dilatation did not
reduce the rate of angiographic restenosis for the CB
compared with conventional balloon angioplasty. CB
angioplasty should be reserved for difficult lesions in
which controlled dilatation is believed to provide a bet-
ter acute result compared with balloon angioplasty
alone. 2002 by Excerpta Medica, Inc.
(Am J Cardiol 2002;90:1079–1083)
The search for a method to dilate an obstructivecoronary lesion without invoking the proportional
injury response observed in already approved devic-
es1,2 led to the development of the cutting balloon
(CB) (Boston Scientific Interventional Technologies,
Natick, Massachusetts), an angioplasty balloon with 3
to 4 longitudinally bonded microtomes that is de-
signed to score atherosclerotic plaque. It was hypoth-
esized that the discrete longitudinal incisions created
during balloon inflation might improve the success of
angioplasty by reducing elastic recoil and minimizing
intimal injury, thereby minimizing the neointimal pro-
liferative response.3,4 Theoretically, this effect may
allow CB angioplasty to achieve and maintain a larger
lumen diameter using lower balloon inflation pres-
sures and durations than conventional percutaneous
transluminal coronary angioplasty (PTCA). Moreover,
by creating controlled incision planes, CB treatment
may reduce rates of major dissection associated with
angioplasty.5 Multiple case series from North Amer-
ica, Europe, and Japan—as well as small randomized
studies—have suggested the safety and utility of CB
angioplasty4,6–10 and a reduction in restenosis in pa-
tients treated with CB compared with PTCA.5,11,12 We
present a large multicenter randomized clinical trial
designed to determine the acute and late-term effects
of CB angioplasty on obstructive coronary disease as
compared with PTCA.
METHODS
Study design: The primary objective of this study
was to evaluate rates of angiographic restenosis after
CB angioplasty as compared with PTCA. The trial
complied with the provisions of the Declaration of
Helsinki, and all investigational sites received ap-
proval from their institutional review boards. Written
informed consent was obtained from all patients.
Criteria for eligibility: Patients aged 25 to 75 years
were eligible for the study if they had evidence of
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myocardial ischemia attributable to a de novo stenosis
20 mm in length in a native coronary artery 2 mm
in diameter. The principal clinical criteria for patient
exclusion were a history of angioplasty of the target
lesion, contraindication to emergency coronary artery
bypass surgery, angina at rest or Q-wave myocardial
infarction within the preceding 48 hours, and concom-
itant congestive heart failure. The angiographic crite-
ria for patient exclusion were total occlusion, presence
of thrombus, severe calcification, ulceration, vessel
angulation of 45°, and American College of Cardi-
ology/American Heart Association class C lesions.13
Coronary intervention: Eligible patients were ran-
domized to a strategy of CB or PTCA. For the CB
strategy, a balloon-to-artery (diameter) ratio was lim-
ited to between 0.9 and 1.1, and a balloon length (10
or 15 mm) to cover the proximal and distal margins of
the lesion was chosen. Tandem inflations were per-
formed for lesions 15 to 20 mm in length. At each site,
a single CB inflation was performed with a final
pressure of 4 to 8 atm for 90 seconds. If a residual
stenosis of 40% was present after CB dilation, sub-
sequent dilations were performed using a conventional
angioplasty balloon. For the PTCA strategy, the final
pressure and duration, and number of balloon infla-
tions were left to the discretion of the operator. All
patients received aspirin and intravenous heparin be-
fore angioplasty. Intracoronary nitroglycerin was ad-
ministered before baseline and postintervention an-
giography.
Collection of data and analyses at the core labora-
tory: Case report forms were completed at each site,
supervised by independent study monitors, and sub-
mitted to the data-coordinating center (Cardiovascular
Data Analysis Center/Harvard Clinical Research In-
stitute, Boston, Massachusetts). An independent clin-
ical events committee that was unaware of each pa-
tient’s treatment assignment adjudicated all major ad-
verse cardiac events.
Angiograms obtained during the procedure and at
the 6-month follow-up were submitted to the angio-
graphic core laboratory (Washington Hospital Center
Angiographic Core Laboratory, Washington, DC). Pa-
tients who developed recurrent symptoms of ischemia
before the scheduled 6-month follow-up also under-
went angiography. Quantitative angiographic analysis
was performed using selected cine frames at baseline
and at the end of the procedure, and at 6 months. A
minimum of a 7Fr guiding catheter was used for
accurate calibration. Reference and minimum lumen
diameters were determined with an automated edge-
detection algorithm (Cardiovascular Measurement
System, Medis Medical Imaging Systems, Nuenen,
The Netherlands). The acute gain, late loss, and late-
loss index were defined as previously described.2,14
Creatine kinase (CK) and isoenzyme (CK-MB)
determinations were performed at 8, 16, and 24 hours
following completion of the procedure, and a 12-lead
electrocardiogram was performed immediately after
the procedure and before hospital discharge. Electro-
cardiograms were submitted to a core laboratory for
analysis (Duke Clinical Research Institute, Durham,
North Carolina). Any patient with signs or symptoms
of ischemia had additional CK and CK-MB determi-
nations recorded.
Study end points: The primary end point for the
present study was binary angiographic restenosis, de-
fined as percent diameter stenosis 50% at 6-month
follow-up. The secondary end points included: acute
procedural success, defined as a composite of attain-
ment of a 50% diameter stenosis in the absence of
in-hospital major adverse cardiac events; acute device
success, defined as the achievement of50% stenosis
of the target lesion without crossover treatment or
unplanned coronary stenting; target lesion revascular-
ization, defined as clinically driven revascularization
of the target lesion; target vessel revascularization,
defined as clinically driven revascularization of any
lesion in the target vessel; and myocardial infarction.
Myocardial infarction was defined as Q wave—the
development of new, pathologic Q waves in 2 con-
tiguous leads with postprocedure CK-MB levels
above normal, or as non–Q-wave—elevation of post-
procedure CK levels to 2 times than normal, with
CK-MB levels above normal in the absence of new,
pathologic Q waves. The major adverse cardiac event
rate, at 30 and at 270 days, was defined as the com-
posite of death, Q-wave myocardial infarction, emer-
gency bypass surgery, and target lesion revasculariza-
tion. The loss index was defined as the slope of the
linear regression model of late loss (dependent vari-
able) and acute gain (independent variable).1
Statistical analysis: The present study was designed
to have a power of 90% to reject the null hypothesis of
no difference between the treatment groups with a 5%
level of significance in 2-tailed tests. On the basis of
an expected 6-month restenosis rate of 40% for the
conventional angioplasty strategy, and 30% for the
CB strategy (25% treatment effect), and assuming
80% angiographic follow-up, a sample size of 1,244
patients was calculated.
All comparisons were performed in accordance
with the intention-to-treat principle. Continuous vari-
ables were compared using Student’s t test if data
were normally distributed and the Wilcoxon rank-sum
test if they were not. Binary variables were compared
using Fisher’s exact test. Survival was estimated using
the Kaplan-Meier method15 and compared using the
log-rank test. A multivariable model of restenosis was
constructed in which the dependent variable was bi-
nary angiographic restenosis at 6 months and the
independent variables were selected baseline covari-
ates. A 2-tailed p value of 0.05 was considered to
indicate significance. All analyses were performed
using SAS software (version 6.12, SAS Institute,
Cary, North Carolina). All data were analyzed accord-
ing to the intention-to-treat principle.
RESULTS
Between April 1994 and November 1996, 1,245
patients were enrolled at 34 investigational sites in
North America and Europe. A total of 1,238 patients
were treated. Six hundred seventeen patients were
randomized to CB treatment, and 621 to PTCA. Seven
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patients were excluded after randomization but before
treatment assignment because of failure to meet eligi-
bility criteria.
Baseline characteristics: The baseline clinical and
angiographic characteristics were similar in patients of
the 2 treatment groups (Tables 1 and 2). Importantly,
the 2 groups were well-matched with respect to vari-
ables known to increase the risk of restenosis—dia-
betes mellitus, Canadian Cardiovascular Society an-
gina class III or IV, and location of lesion in the left
anterior descending artery.16–18 The mean reference
vessel diameter before the procedure was 2.84  0.49
mm for CB and 2.87  0.49 mm for PTCA, whereas
the mean lesion length was 8.9  4.2 and 8.9  4.4
mm, respectively. Both groups had a high prevalence
of current smokers. Most of the treated lesions were
moderately complex (American College of Cardiolo-
gy/American Heart Association grade B1 or B2).13
Acute procedural success: Acute procedural success
was 92.9% for CB and 94.7% for PTCA (p  0.24),
and acute device success was also similar (77.7% vs
77.8%, p 1.0). The balloon-to-artery ratio employed
was similar in the 2 study arms (1.0  0.1 vs 1.0 
0.1). In addition, there were no significant differences
in rates of dissection after the procedure (36% vs 35%,
p  0.34) or “bail-out” stenting (13% vs 16%, p 
0.13). However, CB left a smaller immediate minimal
lumen diameter after the procedure (2.05  0.52 vs
2.13  0.53 mm, p  0.01) and a greater residual
percent diameter stenosis (29  14% vs 27  13%, p
 0.01) than PTCA (Table 3).
Angiographic follow-up: Repeat angiography was
performed at 6 months in 551 (82%) and 559 (80%) of
lesions treated with CB and PTCA, respectively. Dur-
ing the 6-month angiographic follow-up the primary
end point of binary angiographic restenosis was not
significantly different between the 2 groups (CB
31.4% vs PTCA 30.4%, p  0.75; Table 3), and the
follow-up minimal lumen diameter and percent diam-
eter stenosis were also similar (Table 3).
A nonsignificant reduction in lower absolute late
loss at 6 months in the CB arm (0.43  0.61 vs 0.50
 0.60, p  0.06) failed to translate to lower angio-
graphic restenosis rates because CB achieved a
smaller acute gain than PTCA (1.09  0.54 vs 1.15 
0.53, p  0.04). In addition, the proportional response
to injury, as measured by the late loss index, was not
different between CB and PTCA arms (0.49 0.04 vs
0.44  0.05, p  0.3).
Clinical follow-up: At 270 days, clinical follow-up
was available in 580 patients (94%) assigned to CB
and 572 patients (92%) assigned to PTCA. The 30-day
major adverse cardiac event rate was 3.7% for CB
versus 2.7% for PTCA (p  0.34), and the 270-day
major adverse cardiac event rate was 13.6% versus
15.1%, respectively (p  0.47; Table 4). Freedom
from target vessel revascularization, however, was
higher in the group treated with CB (88.5%) compared
with PTCA (84.6%, log-rank p  0.04; Figure 1). In
comparison to the PTCA arm, there was a higher
incidence of myocardial infarction, largely non–Q-
wave, in the CB arm (4.7% for CB vs 2.4% for PTCA,
p  0.03) and higher mortality at 9 months (1.3% vs
0.3%, p  0.06; Table 4).
There were 6 cases of emergency bypass surgery in
each arm of the study (Table 4). Five coronary perfo-
rations occurred in the CB arm, and none occurred in
the conventional angioplasty arm (0.8%, 0%, p 
0.03). Of the 5 perforations, 2 were detected angio-
graphically by the appearance of contrast extravasa-
tion into the periadventitial space without tamponade;
however, 3 perforations were clinically important.
One patient underwent successful pericardiocentesis
for treatment of tamponade. Two other patients died
following perforation, tamponade, and emergency
coronary artery bypass graft surgery. Within the CB
arm, the balloon-to-artery ratio was higher in the cases
of perforation than in the cases without perforation
(mean 1.4  0.4, range 1.1 to 1.8 for perforations vs
1.0  0.1 for nonperforations, p  0.05).
Multivariable regression analysis: Despite adjust-
ment for differences in baseline characteristics and
minimal lumen diameter after the procedure in a mul-
tivariable model, treatment strategy (CB vs PTCA)
TABLE 1 Baseline Demographics and Clinical Characteristics
Patient Characteristic
CB PTCA
(n  617) (n  621)
Age (yrs) 59  10 58  11
Men 72% 77%
Smoking 67% 69%
Diabetes mellitus 13% 12%
Dyslipidemia 45% 47%
Hypertension 34% 37%
Prior myocardial infarction 37% 39%
Prior coronary artery bypass graft surgery 3% 3%
CCS class III or IV angina 64% 64%
Values are expressed as percentages (counts/sample size) or mean  SD.
CCS  Canadian Cardiovascular Society.
TABLE 2 Baseline Angiographic Characteristics
Lesion Characteristic
CB PTCA
(n  689) (n  696)
Lesion length (mm) 8.9  4.2 8.9  4.4
Reference vessel diameter (mm) 2.84  0.49 2.87  0.49
Minimal lumen diameter (mm) 0.96  0.33 0.98  0.34
Diameter stenosis (%) 66  11 66  11
Target vessel
Left anterior descending artery 42% 42%
Left circumflex artery 28% 24%
Right coronary artery 31% 34%
Calcification (moderate or severe) 14% 15%
Thrombus 4% 3%
Eccentric lesion 44% 44%






Values are expressed as percentages (counts/sample size) or mean  SD.
*American College of Cardiology/American Heart Association Lesion
Class.13
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was not a significant independent predictor of 6-month
binary angiographic restenosis.
DISCUSSION
The search for a percutaneous coronary interven-
tion that would relieve obstructive stenosis and mini-
mize the inevitable tissue injury response that leads to
restenosis in a sizeable minority of patients has been
ongoing since the advent of balloon
angioplasty in 1977.1 First proposed
by Schwartz et al,19 the proportional
injury model of balloon dilatation in
porcine coronary arteries demon-
strated that the healing neointimal
response was proportional to the de-
gree of underlying histologic injury
created by the initial balloon dilata-
tion. This model has been upheld in
clinical trials of coronary devices, in
which a consistent proportional rela-
tion has been observed between in-
jury, measured as acute gain im-
parted by the device, and the healing
injury response, measured as the
6-month late loss in lumen diame-
ter.2,20
Despite a wide variety of me-
chanical approaches designed to en-
large coronary lumen size beyond
balloon dilatation alone (including
plaque atherectomy, ablative me-
chanical and laser atherectomy, and
metal stenting), a common propor-
tional vascular injury response ap-
pears to transcend the wide array of
mechanical interventions. That is,
the relation between 6-month late
loss and initial acute gain in the tar-
get lesion lumen diameter for any
given intervention, known as the
late-loss index,1 has been consis-
tently observed to be approximately
50%.
We evaluated whether CB angio-
plasty could reduce rates of resteno-
sis by its proposed mechanism of
controlled injury causing minimal injury response.
The results from this well-powered multicenter trial of
1,238 patients randomized to the CB versus PTCA
demonstrated that the CB was associated with high
rates of procedural success. However, there was no
difference in the primary end point of binary angio-
graphic restenosis between the 2 arms. This primary
negative finding is well-supported by the trial design
with 90% power to detect a 25% treatment effect.
The observation that the late loss index in the CB
arm was no different from that of PTCA, even at the
low pressures and durations used for CB inflation,
suggests that the CB does not reduce the proportional
response to injury. These results and the multivariable
model are consistent with the conclusion that a larger
minimum lumen diameter after the procedure is the
most influential procedural predictor of restenosis,
irrespective of the mechanism of plaque displace-
ment.2
It had been proposed that by creating controlled
linear incisions, CB use could reduce the incidence of
flow-limiting dissection after the procedure. In this
study, however, rates of dissection were the same in
both treatment groups. Perforation is a risk of all
TABLE 3 Quantitative Angiographic Analysis
Lesion Characteristic CB PTCA p Value
Immediatly after procedure
Reference vessel diameter (mm) 2.89  0.49 2.93  0.48 0.13
Minimal lumen diameter (mm) 2.05  0.52 2.13  0.53 0.01
Residual (%) diameter stenosis 29  14 27  13 0.01
Acute gain (mm) 1.09  0.54 1.15  0.53 0.04
At 6-mo follow-up
Reference vessel diameter (mm) 2.79  0.46 2.83  0.47 0.15
Minimal lumen diameter (mm) 1.63  0.62 1.65  0.61 0.44
Diameter stenosis (%) 42  19 42  19 0.99
Binary restenosis rate (50% stenosis) 31.4% 30.4% 0.75
Late loss (mm) 0.43  0.61 0.50  0.60 0.06
Values are expressed as percentages (counts/sample size) or mean  SD.
TABLE 4 Early and Late Adverse Events
Event
CB PTCA
(n  617) (n  621) p Value
Early complications (within 30 days)
Total major adverse cardiac events 23 (3.7%) 17 (2.7%) 0.34
Death 4 (0.6%) 0 0.06
Myocardial infarction 26 (4.2%) 14 (2.3%) 0.05
Q wave 6 (1.0%) 6 (1.0%) 1
Non–Q-wave 20 (3.2%) 8 (1.3%) 0.02
Emergency bypass surgery 6 (1.0%) 6 (1.0%) 1
Target lesion revascularization 16 (2.6%) 16 (2.6%) 1
Subacute closure 8 (1.3%) 10 (1.6%) 0.81
Vessel perforation 5 (0.8%) 0 0.03
Major vascular complications 2 (0.3%) 1 (0.2%) 0.62
Total complications (through 9 mo)
Total major adverse cardiac events 84 (13.6%) 94 (15.1%) 0.47
Death 8 (1.3%) 2 (0.3%) 0.06
Myocardial infarction 29 (4.7%) 15 (2.4%) 0.03
Q wave 9 (1.5%) 7 (1.1%) 0.63
Non–Q-wave 20 (3.2%) 8 (1.3%) 0.02
Emergency bypass surgery 6 (1.0%) 6 (1.0%) 1
Target lesion revascularization 72 (12%) 92 (15%) 0.11
FIGURE 1. Kaplan-Meier estimated freedom from target vessel
revascularization (TVR), demonstrating a higher survival for CB.
(p  0.04).
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percutaneous coronary interventions. Five coronary
perforations occurred after CB treatment (0.8%) and
none after conventional angioplasty (p 0.03). Given
the small number of events, it is difficult to predict
with certainty what procedural variables predispose to
coronary perforation following CB treatment, but high
balloon-to-artery ratios (1.1) were associated with
this complication.
The role of CB may be for difficult lesions in
which controlled dilatation is believed to provide a
better acute result. Since the completion of this study,
CB angioplasty has been proposed, with success in
case series, for the treatment of resistant lesions,10 and
also for the treatment of the in-stent restenotic lesions
with or without vascular brachytherapy.21
In this multicenter, randomized clinical trial, CB
angioplasty did not reduce rates of angiographic re-
stenosis but did reduce the rate of target vessel revas-
cularization. The CB demonstrated excellent acute
procedural results; however, it is an example of an-
other new coronary angioplasty device, that despite its
novel mechanism of plaque displacement results, in
the expected proportional response to injury previ-
ously seen with conventional angioplasty, atherec-
tomy, and stenting. It is unlikely that different me-
chanical solutions will alter the arterial response to
injury enough to prevent restenosis. To reduce the
injury response, we will instead need to look forward
to interventions that address the biology of restenosis,
such as the promising drug-coated stents.22
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